EVALUATING THE REAL-LIFE DAILY-COST OF TREATMENT WITH ANTIEPILEPTIC DRUGS IN FRANCE- A STUDY BASED ON THE COMBINATION OF FRENCH NATIONAL HEALTH INSURANCE PUBLIC DATABASE, AND THE EMR LPD PRIVATE DATABASE.
Author(s)
Troubat A, Bodaghi C, Ansolabehere X, Gibon N, Verschelde S
QuintilesIMS, Paris La Défense, France
OBJECTIVES: To evaluate the real-life daily-cost of treatment with antiepileptic drugs, delivered in retail pharmacies in France. METHODS: Two sources of data were extracted and combined for the purpose of this study. On the one hand, private EMR Longitudinal Patient Data were used to assess the daily dose of antiepileptics prescribed in real life to patients above fifteen RESULTS: The combination of these two real-life insights lead to the estimation of the daily dose with a price per milligram, and the assessment of a daily cost of treatment in real life for each drug. Crossing the two databases between October 2015 and September 2016 showed that among the ten main antiepileptics, the daily cost of treatment ranged from 0,17€ to 3,79€ per day. Medic’AM data also gave access to the substitution ratio between generic and brand-name drugs. It showed that generic drugs accounted for 66% of the amount reimbursed by the French national health insurance. CONCLUSIONS: This analysis shows that combining private data on ambulatory drugs prescriptions and public data on their reimbursement enables the calculation of a real-life daily-cost.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PND22
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders